RAY THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 1
- Market Cap
- -
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Phase 1
Recruiting
- Conditions
- Retinitis PigmentosaChoroideremia
- Interventions
- Genetic: RTx-015
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Ray Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06460844
- Locations
- 🇺🇸
Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Retina Consultants of Texas Research Centers, Bellaire, Texas, United States
🇺🇸UCI Alpha Clinic, Orange, California, United States
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Recruiting
- Conditions
- Retinitis PigmentosaChoroideremiaStargardt Macular DystrophyStargardt DiseaseGeographic Atrophy from Age-related Macular DegenerationX-lined RetinoschisisRetinal Dystrophies
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Ray Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06375239
- Locations
- 🇺🇸
Vision Research and Assessment Institute, Irvine, California, United States
© Copyright 2025. All Rights Reserved by MedPath